1. Home
  2. FLNT vs TTRX Comparison

FLNT vs TTRX Comparison

Compare FLNT & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluent Inc.

FLNT

Fluent Inc.

N/A

Current Price

$3.48

Market Cap

108.5M

ML Signal

N/A

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.42

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FLNT
TTRX
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.5M
116.0M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
FLNT
TTRX
Price
$3.48
$3.42
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$3.50
$8.00
AVG Volume (30 Days)
29.5K
25.6K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
41.67
N/A
EPS
N/A
N/A
Revenue
$208,764,000.00
N/A
Revenue This Year
$5.89
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$2.57
52 Week High
$4.15
$5.98

Technical Indicators

Market Signals
Indicator
FLNT
TTRX
Relative Strength Index (RSI) 54.24 52.30
Support Level $2.93 $2.98
Resistance Level $3.57 $3.82
Average True Range (ATR) 0.23 0.28
MACD 0.01 0.02
Stochastic Oscillator 79.83 80.10

Price Performance

Historical Comparison
FLNT
TTRX

About FLNT Fluent Inc.

Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers company is seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Share on Social Networks: